The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines has authorised the second clinical study with COVID-19 reconvalescent plasma (RECOVER) in Germany. The purpose of such clinical trials is to gain insights into the safety and efficacy of COVID-19 reconvalescent plasma in the treatment of serious COVID-19 infections. Patients to be treated include old and high-risk […]
If you have fully recovered from COVID-19, you may be able to help patients currently fighting the infection by donating your plasma. Because you fought the infection, your plasma now contains COVID-19 antibodies. These antibodies provided one way for your immune system to fight the virus when you were sick, so your plasma may be […]
The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, has granted approval for the first clinical trial with COVID-19 convalescent plasma (CAPSID) in Germany. The aim of the clinical trial is to gain insights into the efficacy and safety of COVID-19 convalescent plasma in the treatment of severe COVID-19 diseases. The ethics committee has also issued […]
Plasma transfusion is a potentially promising therapy for COVID-19 patients that can be made widely available at relatively short notice by blood services across the EU. The Guidance document on the collection and transfusion of convalescent COVID-19 plasma https://ec.europa.eu/health/sites/health/files/blood_tissues_organs/docs/guidance_plasma_covid19_en.pdf Search for available translations of the preceding link••• aims to facilitate a common approach across EU […]
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Japanese
Korean
Portuguese
Russian
Spanish